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Abstract
Background: Pseudoephedrine is a drug commonly prescribed as a nasal decongestant and
bronchodilator and is also freely available in cold remedies and medications. The structural and
pharmacological similarity of pseudoephedrine to amphetamine has led to evaluation of its
psychomotor stimulant properties within the central nervous system. Previous investigations have
shown that the acute responses to pseudoephedrine were similar to those of amphetamine and
other psychostimulants.
Results: This study examined the effect of chronic administration of pseudoephedrine in rat
nucleus accumbens and striatum and identified three further similarities to amphetamine. (i)
Chronic exposure to pseudoephedrine reduced the c-Fos response to acute pseudoephedrine
treatment suggesting that pseudoephedrine induced tolerance in the animals. (ii) In animals
chronically treated with amphetamine or pseudoephedrine the acute c-Fos response to
pseudoephedrine and amphetamine was reduced respectively as compared to naïve animals
indicating cross-tolerance for the two drugs. (iii)The known involvement of the dopamine system
in the response to amphetamine and pseudoephedrine was further confirmed in this study by
demonstrating that pseudoephedrine similarly to amphetamine, but with lower potency, inhibited
[3H]dopamine uptake in synaptosomal preparations.
Conclusion: This work has demonstrated further similarities of the effect of pseudoephedrine to
those of amphetamine in brain areas known to be associated with drug addiction. The most
significant result presented here is the cross tolerance effect of amphetamine and psudoephedrine.
This suggests that both drugs induce similar mechanisms of action in the brain. Further studies are
required to establish whether despite its considerable lower potency, pseudoephedrine could pose
health and addiction risks in humans similar to that of known psychostimulants.
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Pseudoephedrine is a drug commonly prescribed as a
nasal decongestant and bronchodilator and is also availa-
ble in over the counter cold remedy medications. The
chemical structure of pseudoephedrine is similar to that
of the psychostimulant amphetamine and both are classi-
fied as sympathomimetic drugs [1]. Numerous studies
have documented the cellular effects of amphetamine
which include increased dopamine release, inhibition of
dopamine uptake, D1 and D2 dopamine receptor stimu-
lation, cAMP changes, cAMP responsive element binding
protein (CREB) activation, immediate-early gene expres-
sion and activation of other specific genes such as dynor-
phin[2].
Within the central nervous system, the nucleus
accumbens and the striatum have been identified as
important target areas of psychostimulants and opiates
whereby repetitive activation of these areas through
dopaminergic action is believed to play a major role in the
establishment of drug dependence and withdrawal phe-
nomena [3-5].
The expression of immediate-early genes in response to
acute administration of potentially addictive drugs is of
particular interest with respect to the mechanisms that
may trigger dependence. Amphetamine can induce the
expression of c-Fos and jun-B and zif:268. This ability to
acutely induce immediate-early gene expression in the
nucleus accumbens and striatum is now considered to be
a general property of psychostimulant drugs [6-9]. The
induction of c-fos by psychostimulants is believed to be
mediated predominantly via the D1 receptors as demon-
strated by the fact that the D1 specific antagonist
SCH23390 can strongly inhibit amphetamine and
cocaine-induced c-Fos expression and Fos-like immuno-
reactivity [6,10]. However, these findings do not preclude
the involvement of other dopamine receptor types in the
response to psychostimulants [8,11].
Work in our laboratory employing a drug substitution test
indicated that pseudoephedrine elicited, in rats, similar
internal cues to amphetamine [12]. Additionally, we dem-
onstrated that pseudoephedrine induced Fos-like immu-
noreactivity in the nucleus accumbens and striatum
regions in a time and concentration-dependent manner
with maximal effect at 60 mg/kg 2 h after injection [13].
To further investigate the similarity of amphetamine's and
pseudoephedrine's action we have analysed the acute c-
Fos response to psuedoephedrine in rats chronically
treated with pseudoephedrine or amphetamine. Addi-
tionally, we have compared the effect of pseudoephedrine
and amphetamine on dopamine taken up into synapto-
somes prepared from rat nucleus accumbens and stria-
tum. The data further indicates that pseudoephedrine
operates in a manner similar to amphetamine which may
have implications for its over-the-counter use.
Methods
Animal treatments
All animal procedures were carried out in compliance
with Mahidol University Code of Practice and the
National Institutes of Health (USA) Guidelines for treat-
ment of laboratory animals. Male Sprague-Dawley rats
(between 200 and 250 g) were obtained from the
National Animal Center, Mahidol University, Thailand,
housed in groups of 6 and maintained on a 12 h light/
dark cycle with free access to water and food. All animals
were handled for at least 1 week before the experiment. In
acute treatment, rats were injected intraperitoneally (i.p.)
with pseudoephedrine (40 mg/kg, i.p.) or d-ampheta-
mine (3 mg/kg, i.p.) and were killed 1.5 h after the drug
injection. In chronic treatment, rats were injected twice a
day (8.30 a.m. and 6.30 p.m.) for 8 days with pseu-
doephedrine (Sigma, Aldrich St. Louis USA) at increasing
doses of 25, 30, 35, 40 mg/kg, i.p. on day 1, 2, 3 and 4–8
respectively. To study cross tolerance with amphetamine,
rats were chronically injected twice a day (8.30 a.m. and
6.30 p.m.) for 8 days with d-amphetamine at increasing
doses of 1, 2, 2.5, 3 mg/kg, i.p. on day 1, 2, 3 and 4–8
respectively. Rats were sacrificed on day 9, 1.5 h after the
last injection of either d-pseudoephedrine (40 mg/kg,
i.p.), d-amphetamine (3 mg/kg, i.p.) or saline. The final
injection on day 9 was carried out at 8:30 a.m. as during
the chronic treatment.
Nuclear extract preparation
Under the stereodissecting microscope, the rat brains were
cut coronally at the optic chiasma and 2 mm more fron-
tally. From this section striatum and nucleus accumbens
were manually dissected. The striatum was identified as
the striated area below the corpus callosum while the
nucleus accumbens as the area surrounding the anterior
commisure which is easily identifiable as a small white
area. The dissected tissues were used for nuclei isolation as
previously described [14]. To obtain sufficient tissue,
brain areas from 2–3 similarly treated animals were
pooled and homogenized in 2 ml of chilled solution I
(0.32 M sucrose, 3 mM MgCl2, 1 mM Hepes, pH 6.8)
using a glass Teflon homogenizer. The crude homogenate
was transferred to a new centrifuge tube and diluted with
1.2 ml of solution I and 0.44 ml of distilled water. The
diluted homogenate was underlaid with 3 ml of solution
I, and centrifuged at 1000 × g for 10 min. The pellet was
harvested and resuspended in 5.33 ml of solution II (1.4
M sucrose, 1 mM MgCl2, 1 mM Hepes, pH 6.8), and cen-
trifuged at 50,000 × g for 10 min in a fixed angle rotor. The
nuclear pellet was harvested and resuspended in 18–20 μl
of solution III (0.25 M sucrose, 1 mM MgCl2, 1 mM
Hepes, pH 6.8). Protein concentration was determined byPage 2 of 8
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was used as a standard.
Western blot
Western blots were carried out as previously described
[13]. Nuclear extract samples were mixed with an equal
volume of loading buffer (0.1 M Tris (pH 6.8), 4%
sodium dodecyl sulphate (w/v), 20% glycerol (w/v), 0.2
M of 1,4-Dithiothreitol (DTT) and 0.2% bromophenol
blue (w/v), boiled for 5 min, electrophoresed on 10% dis-
continuous sodium dodecyl sulphate acrylamide gel and
electroblotted to nitrocellulose membrane. Following
transfer, the membrane was briefly washed in transfer
buffer, and incubated in blocking solution (0.02 M Tris,
pH 7.4, 0.15 M NaCl, 5% non-fat dried milk (w/v), 0.05%
Tween 20 (v/v)) for 2 h at room temperature. The mem-
brane was incubated with anti-Fos antibodies (Genosys
Ltd., UK.) 1:500 in blocking solution for 1.5 h, washed 4
× 7 min with 50 ml of TBST solution (0.2 M Tris (pH 7.4),
1.5 M NaCl, 0.5% Tween 20 (v/v)) incubated with alka-
line phosphatase-conjugated anti-sheep immunoglobulin
antibody (Sigma, St. Louis USA) diluted 1:1000 in block-
ing solution for 1 h at room temperature and washed first
4 × 7 min with 50 ml of TBST solution and finally 7 min
with 50 ml of TBS solution (0.2 M Tris (pH 7.4), 1.5 M
NaCl). Bands were visualized after addition of Western
Blue (Promega, USA) stabilized substrate for alkaline
phosphatase. The staining of the specifically labeled 55
KDa c-Fos band was scanned on a flat bed scanner and
quantified with the NIH software program.
Synaptosome preparation
Male Sprague Dawley rats weighing 200–250 g were killed
by decapitation and brains were rapidly removed and
cooled on ice. The synaptosomes were prepared as previ-
ously described [16] with some modifications. The stria-
tum and nucleus accumbens were dissected, weighed and
homogenized using a glass teflon homogenizer in 20 vol-
umes of 0.32 M sucrose, 0.12 mM KH2PO4 and 0.5 mM
Na2HPO4 (pH 7.4) at 4°C. Homogenates were centri-
fuged at 900 × g for 10 min. The supernatant was further
centrifuged at 11,000 × g for 20 min, The pellet was resus-
pended in an ice cold Krebs phosphate buffer containing
127.2 mM NaCl, 5 mM KCl, 1.3 mM MgSO4, 1.2 mM
KH2PO4, 5 mM Na2HPO4, 1.25 mM CaCl2, 1 mM
EDTA, 0.105 mM ascorbic acid, 1.05 μM pargyline and
11.1 mM glucose (pH 7.4).
[3H]Dopamine uptake
Measurement of [3H]dopamine uptake into synapto-
somes was carried out according to previously published
methods [17,18]. Test drugs (50 μl of d-amphetamine or
d-pseudoephedrine) followed by 50 μl [3H]dopamine
(final concentration 1 nM) were added to synaptosomal
suspensions (900 μl, final protein concentration of stri-
atal and nucleus accumbens synaptosomes were 0.44 ±
0.01 mg/ml and 0.23 ± 0.01 mg/ml respectively) to give a
final volume of 1 ml. The reaction mixture was incubated
at 25°C for 5 min in a metabolic shaker water bath. Fol-
lowing incubation, the reaction mixture was rapidly fil-
tered through glass-fiber filter paper (Whatman GF/B) by
a vacuum pump and washed twice with 3 ml of Krebs
phosphate buffer. The synaptosomes containing radioac-
tive dopamine trapped on filter paper were counted by
liquid scintillation spectrometry (Beckman LS 1801) in 5
ml of TritonX-100/Toluene base fluor (1:3) scintillation
fluid. The active accumulation of [3H]dopamine was
determined as the difference of the radioactivity accumu-
lated in the synaptosomes in the presence and absence of
1 μM nomifensine.
The inhibition was determined as percent of controls and
the IC50 values were calculated from at least four separate
experiments, each conducted in duplicates, and the 95%
confidence limits were calculated by non-linear regression
analysis from the approximately linear part of the log con-
centration response curves.
Statistical analysis
All c-Fos expression values are optical density measure-
ments (arbitrary units) and are represented as mean ±
S.E.M normalized to 100% of control. A one-way analysis
of variance (ANOVA) was used. Post-hoc tests were per-
formed using the Tukey test to compare significance
between the individual groups. The significance was taken
when p-values were less than 0.05.
Results
Effect of chronic pseudoephedrine treatment on the c-Fos 
acute response to pseudoephedrine in nucleus accumbens 
and striatum
The relative c-Fos response in nucleus accumbens and
striatum was measured by densitometry of immunos-
tained bands in a Western blot assay. Pseudoephedrine
(40 mg/kg, i.p.) induced an acute increase in c-Fos expres-
sion in the nucleus accumbens and striatum as compared
with saline-treated rats (Fig. 1). The peak c-Fos response
was reached at 1.5 hours after treatment. It was main-
tained for up to 30 further minutes and was just above
control at 3 hours after treatment (results not shown). The
bands represent the 55 KDa c-Fos peptide.
To determine effect of pseudoephedrine chronic treat-
ment, rats were chronically injected with either saline or
pseudoephedrine twice a day for 8 days and sacrificed 1.5
h after a final psuedoephedrine injection on day 9.
Chronic exposure to pseudoephedrine significantly
reduced (p < 0.05) the acute c-Fos response to pseu-
doephedrine in the nucleus accumbens and striatum asPage 3 of 8
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Pseudoephedrine induced c-Fos expressionFig re 1
Pseudoephedrine induced c-Fos expression. Western blot analysis was used to measure the acute pseudoephedrine (40 
mg/kg, i.p) induced c-Fos expression in striatum and nucleus accumbens. c-Fos protein was detected 1.5 h after saline and pseu-
doephedrine injection.
Effect of chronic drug treatment on acute c-Fos responseFigure 2
Effect of chronic drug treatment on acute c-Fos response. Western blot analysis was used to measure the acute pseu-
doephedrine induced c-Fos expression in striatum (n = 4) and nucleus accumbens (n = 3) of rats chronically treated with pseu-
doephedrine (8 day treatment of pseudoephedrine twice a day with an increasing dose at 25, 30, 35, 40 mg/kg i.p., on day 1, 2, 
3 and 4–8 respectively, rats were killed 1.5 h after 40 mg/kg, i.p pseudoephedrine injection on day 9). The data (quantification 
of bands from western blots) is expressed as percentage of c-Fos value of control animals injected with saline. (A value of 100% 
indicates no difference from control) Values are mean ± S.E.M. 'a' indicates significantly different from control and chronic; 'b' 
indicates significantly different from acute with p < 0.05.
BMC Neuroscience 2008, 9:99 http://www.biomedcentral.com/1471-2202/9/99compared with animals chronically treated with saline
(Fig. 2).
Cross tolerance between pseudoephedrine and 
amphetamine
The following experiments were designed to test whether
chronic treatment with pseudoephedrine also affected the
acute response to other psychostimulants. Rats were
chronically injected with either saline, amphetamine or
psuedoephedrine for 8 days as described, and on day 9
they received a final injection of either pseudoephedrine
or amphetamine respectively (i.e. pseudoephedrine
treated rats received a final injection of amphetamine and
vice versa) and sacrificed 1.5 h after the last injection.
Measurements of c-Fos expression in the nucleus
accumbens and striatum indicated that chronic treatment
with either amphetamine or pseudoephedrine caused a
reduction (p < 0.005) in the acute response to both drugs
(Fig. 3) indicating that pseudoephedrine and ampheta-
mine have cross tolerance and may use a common path-
way to induce the expression of c-Fos protein.
The effects of d-pseudoephedrine on [3H]dopamine 
uptake
In order to investigate the mechanism of action of pseu-
doephedrine and to compare it to that of amphetamine,
the effect of pseudoephedrine and amphetamine on
[3H]dopamine uptake was assayed in synaptosomal prep-
arations from rat brain areas. Both amphetamine and
pseudoephedrine inhibited the uptake of [3H]dopamine
into nucleus accumbens and striatal synaptosomes, with
amphetamine being more potent than pseudoephedrine
(Fig. 4). The amphetamine and pseudoephedrine curves
were parallel to each other with the curve for pseudoephe-
drine inhibition of [3H]dopamine uptake shifted to the
right. The IC50 values for amphetamine and pseudoephe-
drine inhibition reported here (see legend Fig. 4) indicate
that amphetamine was 156 and 180 times more potent
than pseudoephedrine at inhibiting [3H]dopamine
uptake into striatal and nucleus accumbens synapto-
somes, respectively.
Discussion
Chronic injection of pseudoephedrine resulted in desen-
sitisation of the acute pseudoephedrine induced c-Fos
induction in the striatum and nucleus accumbens. It has
previously been shown that chronic treatment with
cocaine and amphetamine reduces the immediate-early-
gene expression response to these drugs in specific brain
areas [19-21]. Pseudoephedrine effects on c- Fos expres-
sion is thus similar to that of other psychostimulants both
at the acute and chronic level. The c-Fos response to psy-
chomotor stimulant drugs appears to be a direct response
to the drug rather than to a general drug-related altered
state. For example other studies have shown that there are
no significant changes in c-Fos expression following with-
drawal from chronic treatment of psychostimulants (22).
To further test the hypothesis that amphetamine and
pseudoephedrine work through similar mechanisms,
cross tolerance tests were carried out. The results indicate
that in amphetamine and in pseudoephedrine chronically
treated rats the c-Fos response in the striatum and nucleus
accumbens following a final injection with pseudoephe-
drine and amphetamine respectively, was lower than in
naïve animals. This result is consistent with our previous
findings that pseudoephedrine has similar effects and
mechanisms of action as amphetamine in terms of c-Fos
expression [13] and internal behavioral cues [12]. In this
work we have also analysed another reported effect of psy-
chostimulants namely inhibition of [3H]dopamine
uptake and report that both amphetamine and pseu-
doephedrine inhibit [3H]dopamine uptake. The role of
dopamine in pseudoephedrine induced c-Fos response is
further corroborated by the effect of the D1 receptor
antagonist SCH23390 which as previously described [13]
inhibited acute response to pseudoephedrine (results not
shown).
Conclusion
Our studies thus indicate that pseudoephedrine, notwith-
standing the higher doses required, acts in manner indis-
tinguishable from amphetamine. This may have
sociological and medical implications as pseudoephe-
drine is a legal over-the-counter drug. Doses of pseu-
doephedrine in over-the-counter formulations vary
between 60–120 mg/pill and a large amount of pills
would need to be ingested to equate the doses injected
into rats in this study. However, it is unknown whether
the efficacy of the pseudoephedrine in humans is different
from rats. An additional potential risk of pseudoephe-
drine is reinstatement of drug seeking behaviour in indi-
viduals that have overcome previous addiction to
psychostimulants. It would be useful to determine
whether pseudoephedrine could induce a reinstatement
of drug seeking behaviour in rats that had first been
chronically treated with amphetamine and that had then
been allowed to extinguish their amphetamine seeking
behaviour. Particular attention would need to be paid to
the genetic background of the animals as it has been
shown to affect relapse behaviour [23]. The data here
reported and the additional approach described above
would inform further studies in human subjects aimed at
determining the potency of pseudoephedrine in humans
to identify what doses may constitute a health, addiction
or relapse risk.
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